ATOS · Atossa Therapeutics, Inc.

The 2026 Annual Meeting reflects routine corporate governance actions, but the narrow approval of the reverse stock split amendment — with only a ~500,000-vote margin — signals meaningful shareholder skepticism about potential dilution management or listing compliance motives. The absence of broker non-votes for the auditor ratification and reverse split proposals suggests full instruction on those items, contrasting sharply with the director elections and advisory pay vote, both of which carried over two million broker non-votes — likely due to NYSE or NASDAQ rules prohibiting discretionary voting on non-routine matters. While the election of three new Class II directors refreshes board composition, no biographical details, term lengths, or committee assignments are disclosed, limiting insight into strategic oversight capacity. The advisory compensation vote’s low affirmative count relative to total shares outstanding (8.6 million as of record date) implies muted support among voting shareholders, though the high broker non-vote count prevents definitive interpretation. No forward-looking disclosures, financial results, or material agreements accompany this filing, confirming its procedural rather than operational significance.